2013 was the year that my mighty warrior Caeleb was in the hospital more than he was at home. and Christmas was a holiday that was spent in the hospital. Instead of feeling sorry for the fact that my son was in the hospital unable to walk, I…

In this series of podcasts from Bloodstream Media and shared by Bloodfeed, host Patrick James Lynch submits questions about hemophilia and other bleeding disorders from listeners to various hemophilia and health care experts. MORE: Learn more about the Hemophilia CHOICE Project Survey The podcasts feature a pediatric…

A new analysis of two Phase 3 clinical trials confirms that extending preventive treatment with Alprolix is safe and leads to markedly decreases in bleeding episodes of severe hemophilia B patients. The results were recently presented at the 59th Annual Meeting of the American Society of Hematology (ASH) in…

The majority of hemophilia cases are genetic, affect males and are diagnosed fairly early in childhood. However, there are rare cases of hemophilia that develop later in life and are called “acquired hemophilia.” MORE: Four hemophilia screening tests. Acquired hemophilia is an autoimmune disease where the immune system attacks blood clotting factor…

The severity of a person’s hemophilia depends on the amount of clotting factor they have in their blood. Generally speaking, the disease is considered mild, moderate or severe, although around 70 percent of people living with the disease have the severe form. MORE: Five tips for healthy living with hemophilia…

A hemophilia gene therapy developed by Spark Therapeutics and Pfizer nearly eliminated bleeding episodes in 10 patients who took part in a Phase 1/2 trial. The treatment, SPK-9001, worked so well in eight of the 10 that they were able to stop taking clotting factor replacements. Researchers published the preliminary trial…

The first recorded mention of hemophilia came in the second century when a collection of ancient Jewish writings noted that baby boys did not need to be circumcised if two of their older brothers had bled to death following the procedure. Later in the 10th century, an Arabian doctor described cases of…

Shire and Rani Therapeutics have partnered to investigate the use of oral Rani Pill technology as the carrier system for clotting factor VIII in hemophilia A patients. As part of Shire’s commitment, the Irish pharmaceutical company made an equity investment in Rani. Under the agreement — whose terms weren’t…

https://www.youtube.com/watch?v=sK2EIwmIYPo This video from the Bleeding Disorders Community focuses on sports for children with hemophilia. It explains that physical activity is important for people living with hemophilia, as it helps build muscle strength and maintain physical fitness, but that not all sports are suitable for those living…

Nuwiq, a fourth-generation genetically engineered version of blood-clotting factor VIII, is a safe and effective way of controlling bleeding in people with severe hemophilia A during and after surgery, a study reports. The research, “Efficacy and safety of Nuwiq® (human-cl rhFVIII) in patients with severe haemophilia A undergoing…